{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:21:02Z","timestamp":1783488062107,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["32003B_185111"],"award-info":[{"award-number":["32003B_185111"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research grant by Mind Medicine, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>3,4-Methylenedioxymethamphetamine (MDMA) is used recreationally, as a research tool, and in MDMA-assisted therapy in patients with posttraumatic stress disorder. 3,4-Methylenedioxyamphetamine (MDA) is a psychoactive metabolite of MDMA. Acute effects of MDMA and MDA have never been directly compared in humans. Lysine-conjugated amphetamines slowly release active amphetamine once absorbed, suggesting pharmaceutical strategies to enhance tolerability and reduce abuse potential. Therefore, lysine-MDMA (Lys-MDMA) and lysine-MDA (Lys-MDA) were developed as prodrugs of MDMA and MDA, respectively. We used a double-blind, randomized, placebo-controlled, crossover design to compare acute responses to MDMA (100\u2009mg), MDA (92\u2009mg), Lys-MDMA (172\u2009mg), and Lys-MDA (164\u2009mg) at equimolar doses and placebo in 23 healthy participants (12 women, 11 men). Outcome measures included acute subjective, autonomic, and endocrine effects and pharmacokinetics. Compared with placebo, MDMA and MDA produced pronounced subjective and autonomic effects. After Lys-MDMA administration, no MDMA was detected in blood samples, and no corresponding subjective or autonomic effects were observed. MDA produced stronger and longer-lasting subjective \u201cany drug effects\u201d compared with MDMA, with effect durations of (mean\u2009\u00b1\u2009SEM) 6.1\u2009\u00b1\u20090.5 vs 4.1\u2009\u00b1\u20090.4\u2009h, respectively. Additionally, compared with MDMA, MDA induced greater subjective \u201cstimulant effects,\u201d more negative \u201cbad drug effects,\u201d more \u201cfear,\u201d and more \u201cvisual alterations.\u201d Lys-MDA, compared with MDA, showed longer times to onset and maximal effect (1.1\u2009\u00b1\u20090.2\u2009h and 3.0\u2009\u00b1\u20090.4\u2009h vs. 0.7\u2009\u00b1\u20090.1\u2009h and 2.0\u2009\u00b1\u20090.1\u2009h) but otherwise induced similar effects. The plasma elimination half-lives (geometric mean) of MDMA and MDA were 7.3 and 8.4\u2009h, respectively. In summary, MDA produced longer-lasting, stronger, more psychedelic-like perceptual acute effects and more adverse effects compared with MDMA when administered at equimolar doses. Lys-MDA represents a functional slow-release prodrug form of MDA, delaying both the onset and peak of subjective effects. In contrast, Lys-MDMA did not release MDMA, likely because of its tertiary amine structure, and thus does not represent a functional prodrug of MDMA. These results highlight MDA\u2019s less favorable therapeutic profile relative to MDMA and identify lysine conjugation as a potential strategy for modulating, but not necessarily improving, the tolerability of its effects. Trial registration: ClinicalTrials.gov identifier: NCT04847206.<\/jats:p>","DOI":"10.1038\/s41386-025-02248-3","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:35:58Z","timestamp":1758818158000},"page":"476-485","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants"],"prefix":"10.1038","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2952-586X","authenticated-orcid":false,"given":"Isabelle","family":"Straumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5954-4446","authenticated-orcid":false,"given":"Patrick","family":"Vizeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidora","family":"Avedisian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Erne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Noorshams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Vukalovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9341-3669","authenticated-orcid":false,"given":"Anne","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0874-4875","authenticated-orcid":false,"given":"Dino","family":"Luethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3069-9732","authenticated-orcid":false,"given":"Deborah","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1765-9659","authenticated-orcid":false,"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"2248_CR1","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1093\/scan\/nst161","volume":"9","author":"CM Hysek","year":"2014","unstructured":"Hysek CM, Schmid Y, Simmler LD, Domes G, Heinrichs M, Eisenegger C, et al. MDMA enhances emotional empathy and prosocial behavior. Soc Cogn Affect Neurosci. 2014;9:1645\u201352.","journal-title":"Soc Cogn Affect Neurosci"},{"key":"2248_CR2","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/S2213-8587(23)00120-1","volume":"11","author":"C Atila","year":"2023","unstructured":"Atila C, Holze F, Murugesu R, Rommers N, Hutter N, Varghese N, et al. Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trial. Lancet Diabetes Endocrinol. 2023;11:454\u201364.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2248_CR3","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","volume":"29","author":"Mitchell","year":"2023","unstructured":"Mitchell, Ot\u2019alora GM JM, van der Kolk B, Shannon S, Bogenschutz M, Gelfand Y, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29:2473\u201380.","journal-title":"Nat Med"},{"key":"2248_CR4","doi-asserted-by":"publisher","first-page":"e36476","DOI":"10.1371\/journal.pone.0036476","volume":"7","author":"CM Hysek","year":"2012","unstructured":"Hysek CM, Simmler LD, Nicola V, Vischer N, Donzelli M, Kr\u00e4henb\u00fchl S, et al. Duloxetine inhibits effects of MDMA (\u201cecstasy\u201d) in vitro and in humans in a randomized placebo-controlled laboratory study. PLoS One. 2012;7:e36476.","journal-title":"PLoS One"},{"key":"2248_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/00005053-197610000-00002","volume":"163","author":"R Yensen","year":"1976","unstructured":"Yensen R, Di Leo FB, Rhead JC, Richards WA, Soskin RA, Turek B, et al. MDA-assisted psychotherapy with neurotic outpatients: a pilot study. J Nerv Ment Dis. 1976;163:233\u201345.","journal-title":"J Nerv Ment Dis"},{"key":"2248_CR6","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1111\/bph.13128","volume":"172","author":"A Rickli","year":"2015","unstructured":"Rickli A, Kopf S, Hoener MC, Liechti ME. Pharmacological profile of novel psychoactive benzofurans. Br J Pharm. 2015;172:3412\u201325.","journal-title":"Br J Pharm"},{"key":"2248_CR7","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9:3897\u2013902.","journal-title":"Neuroreport"},{"key":"2248_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","volume":"46","author":"F Holze","year":"2021","unstructured":"Holze F, Vizeli P, Ley L, Muller F, Dolder P, Stocker M, et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2021;46:537\u201344.","journal-title":"Neuropsychopharmacology"},{"key":"2248_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41398-024-03116-2","volume":"14","author":"A Klaiber","year":"2024","unstructured":"Klaiber A, Schmid Y, Becker AM, Straumann I, Erne L, Jelusic A, et al. Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects. Transl Psychiatr. 2024;14:395.","journal-title":"Transl Psychiatr"},{"key":"2248_CR10","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/17470910802649470","volume":"4","author":"GJ Dumont","year":"2009","unstructured":"Dumont GJ, Sweep FC, van der Steen R, Hermsen R, Donders AR, Touw DJ, et al. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc Neurosci. 2009;4:359\u201366.","journal-title":"Soc Neurosci"},{"key":"2248_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.psyneuen.2014.04.006","volume":"46","author":"MG Kirkpatrick","year":"2014","unstructured":"Kirkpatrick MG, Francis SM, Lee R, de Wit H, Jacob S. Plasma oxytocin concentrations following MDMA or intranasal oxytocin in humans. Psychoneuroendocrinology. 2014;46:23\u201331.","journal-title":"Psychoneuroendocrinology"},{"key":"2248_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/02791072.2019.1593560","volume":"51","author":"MJ Baggott","year":"2019","unstructured":"Baggott MJ, Garrison KJ, Coyle JR, Galloway GP, Barnes AJ, Huestis MA, et al. Effects of the psychedelic amphetamine MDA (3,4-methylenedioxyamphetamine) in healthy volunteers. J Psychoact Drugs. 2019;51:108\u201317.","journal-title":"J Psychoact Drugs"},{"key":"2248_CR13","doi-asserted-by":"publisher","first-page":"e14074","DOI":"10.1371\/journal.pone.0014074","volume":"5","author":"MJ Baggott","year":"2010","unstructured":"Baggott MJ, Siegrist JD, Galloway GP, Robertson LC, Coyle JR, Mendelson JE. Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans. PLoS One. 2010;5:e14074.","journal-title":"PLoS One"},{"key":"2248_CR14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1177\/0269881109103113","volume":"23","author":"DR Jasinski","year":"2009","unstructured":"Jasinski DR, Krishnan S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol. 2009;23:419\u201327.","journal-title":"J Psychopharmacol"},{"key":"2248_CR15","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1111\/j.1360-0443.1991.tb01754.x","volume":"86","author":"M Farre","year":"1991","unstructured":"Farre M, Cami J. Pharmacokinetic considerations in abuse liability evaluation. Br J Addict. 1991;86:1601\u20136.","journal-title":"Br J Addict"},{"key":"2248_CR16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2165\/00003088-198611020-00004","volume":"11","author":"U Busto","year":"1986","unstructured":"Busto U, Sellers EM. Pharmacokinetic determinants of drug abuse and dependence. A conceptual perspective. Clin Pharmacokinet. 1986;11:144\u201353.","journal-title":"Clin Pharmacokinet"},{"key":"2248_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02477-4","volume":"13","author":"SB Vogt","year":"2023","unstructured":"Vogt SB, Ley L, Erne L, Straumann I, Becker AM, Klaiber A, et al. Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants. Transl Psychiatry. 2023;13:172.","journal-title":"Transl Psychiatry"},{"key":"2248_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.2165\/0044011-200828120-00002","volume":"28","author":"SM Krishnan","year":"2008","unstructured":"Krishnan SM, Pennick M, Stark JG. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. Clin Drug Investig. 2008;28:745\u201355.","journal-title":"Clin Drug Investig"},{"key":"2248_CR19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3389\/fphar.2017.00617","volume":"8","author":"PC Dolder","year":"2017","unstructured":"Dolder PC, Strajhar P, Vizeli P, Hammann F, Odermatt A, Liechti ME. Pharmacokinetics and pharmacodynamics of lisdexamfetamine compared with D-amphetamine in healthy subjects. Front Pharm. 2017;8:617.","journal-title":"Front Pharm"},{"key":"2248_CR20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cts.12692","volume":"13","author":"KE Caudle","year":"2020","unstructured":"Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, et al. Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci. 2020;13:116\u201324.","journal-title":"Clin Transl Sci"},{"key":"2248_CR21","volume-title":"Die Eigenschaftsw\u00f6rterliste","author":"W Janke","year":"1978","unstructured":"Janke W, Debus G. Die Eigenschaftsw\u00f6rterliste. G\u00f6ttingen: Hogrefe; 1978."},{"key":"2248_CR22","doi-asserted-by":"publisher","first-page":"e12412","DOI":"10.1371\/journal.pone.0012412","volume":"5","author":"E Studerus","year":"2010","unstructured":"Studerus E, Gamma A, Vollenweider FX. Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS ONE. 2010;5:e12412.","journal-title":"PLoS ONE"},{"key":"2248_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1177\/02698811231199112","volume":"38","author":"K Stocker","year":"2024","unstructured":"Stocker K, Hartmann M, Ley L, Becker AM, Holze F, Liechti ME. The revival of the psychedelic experience scale: revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies. J Psychopharmacol. 2024;38:80\u2013100.","journal-title":"J Psychopharmacol"},{"key":"2248_CR24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187:268\u201383.","journal-title":"Psychopharmacology"},{"key":"2248_CR25","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1177\/0269881115609019","volume":"29","author":"FS Barrett","year":"2015","unstructured":"Barrett FS, Johnson MW, Griffiths RR. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol. 2015;29:1182\u201390.","journal-title":"J Psychopharmacol"},{"key":"2248_CR26","volume-title":"M\u00fcnchener Informationssystem","author":"DV Zerssen","year":"1976","unstructured":"Zerssen DV Die Beschwerden-Liste. In: M\u00fcnchener Informationssystem. M\u00fcnchen: Psychis; 1976."},{"key":"2248_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.711255","volume":"12","author":"F Holze","year":"2021","unstructured":"Holze F, Avedisian I, Varghese N, Eckert A, Liechti ME. Role of the 5-HT2A receptor in acute effects of LSD on empathy and circulating oxytocin. Front Pharmacol. 2021;12:711255.","journal-title":"Front Pharmacol"},{"key":"2248_CR28","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/ejendo\/lvaf078","volume":"192","author":"C Atila","year":"2025","unstructured":"Atila C, Nikaj A, Leibnitz S, Liechti ME, Christ-Crain M. Neurophysin I: a reliable, novel, and robust biomarker for oxytocin. Eur J Endocrinol. 2025;192:502\u201310.","journal-title":"Eur J Endocrinol"},{"key":"2248_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2024.124123","volume":"1238","author":"D Luethi","year":"2024","unstructured":"Luethi D, Rudin D, Straumann I, Thomann J, Avedisian I, Liechti ME, et al. Derivatization-free determination of chiral plasma pharmacokinetics of MDMA and its enantiomers. J Chromatogr B Anal Technol Biomed Life Sci. 2024;1238:124123.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"2248_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.906639","volume":"13","author":"P Vizeli","year":"2022","unstructured":"Vizeli P, Straumann I, Duthaler U, Varghese N, Eckert A, Paulus MP, et al. Effects of 3,4-methylenedioxymethamphetamine on conditioned fear extinction and retention in a crossover study in healthy subjects. Front Pharm. 2022;13:906639.","journal-title":"Front Pharm"},{"key":"2248_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.pnpbp.2018.03.003","volume":"84","author":"AA Feduccia","year":"2018","unstructured":"Feduccia AA, Mithoefer MC. MDMA-assisted psychotherapy for PTSD: are memory reconsolidation and fear extinction underlying mechanisms?. Prog Neuropsychopharmacol Biol Psychiatry. 2018;84:221\u201328.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2248_CR32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.biopsych.2014.10.015","volume":"78","author":"M Eckstein","year":"2015","unstructured":"Eckstein M, Becker B, Scheele D, Scholz C, Preckel K, Schlaepfer TE, et al. Oxytocin facilitates the extinction of conditioned fear in humans. Biol Psychiatry. 2015;78:194\u2013202.","journal-title":"Biol Psychiatry"},{"key":"2248_CR33","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/0269881109102787","volume":"23","author":"PO Johansen","year":"2009","unstructured":"Johansen PO, Krebs TS. How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. J Psychopharmacol. 2009;23:389\u201391.","journal-title":"J Psychopharmacol"},{"key":"2248_CR34","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.neubiorev.2006.09.009","volume":"31","author":"K Allott","year":"2007","unstructured":"Allott K, Redman J. Are there sex differences associated with the effects of ecstasy\/3,4-methylenedioxymethamphetamine (MDMA)?. Neurosci Biobehav Rev. 2007;31:327\u201347.","journal-title":"Neurosci Biobehav Rev"},{"key":"2248_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s002130000648","volume":"154","author":"ME Liechti","year":"2001","unstructured":"Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology. 2001;154:161\u20138.","journal-title":"Psychopharmacology"},{"key":"2248_CR36","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1177\/0269881117691569","volume":"31","author":"P Vizeli","year":"2017","unstructured":"Vizeli P, Liechti ME. Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol. 2017;31:576\u201388.","journal-title":"J Psychopharmacol"},{"key":"2248_CR37","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41386-024-01972-6","volume":"50","author":"I Straumann","year":"2024","unstructured":"Straumann I, Avedisian I, Klaiber A, Varghese N, Eckert A, Rudin D, et al. Acute effects of R-MDMA, S-MDMA, and racemic MDMA in a randomized double-blind crossover trial in healthy participants. Neuropsychopharmacology. 2024;50:362\u201372.","journal-title":"Neuropsychopharmacology"},{"key":"2248_CR38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/FPC.0000000000000231","volume":"26","author":"Y Schmid","year":"2016","unstructured":"Schmid Y, Vizeli P, Hysek CM, Prestin K, Meyer zu Schwabedissen HE, Liechti ME. CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of MDMA in a controlled study in healthy subjects. Pharmacogenetics Genom. 2016;26:397\u2013401.","journal-title":"Pharmacogenetics Genom"},{"key":"2248_CR39","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1177\/0269881116631650","volume":"30","author":"CT Smith","year":"2016","unstructured":"Smith CT, Weafer J, Cowan RL, Kessler RM, Palmer AA, de Wit H, et al. Individual differences in timing of peak positive subjective responses to d-amphetamine: relationship to pharmacokinetics and physiology. J Psychopharmacol. 2016;30:330\u201343.","journal-title":"J Psychopharmacol"},{"key":"2248_CR40","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1176\/appi.ajp.160.11.1909","volume":"160","author":"ND Volkow","year":"2003","unstructured":"Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry. 2003;160:1909\u201318.","journal-title":"Am J Psychiatry"},{"key":"2248_CR41","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1177\/0269881120920420","volume":"35","author":"HE Oeri","year":"2021","unstructured":"Oeri HE. Beyond ecstasy: alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy. J Psychopharmacol. 2021;35:512\u201336.","journal-title":"J Psychopharmacol"},{"key":"2248_CR42","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1111\/jnc.16149","volume":"168","author":"AS Alberto-Silva","year":"2024","unstructured":"Alberto-Silva AS, Hemmer S, Bock HA, da Silva LA, Scott KR, Kastner N, et al. Bioisosteric analogs of MDMA: improving the pharmacological profile?. J Neurochem. 2024;168:2022\u201342.","journal-title":"J Neurochem"},{"key":"2248_CR43","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1523\/JNEUROSCI.08-08-02788.1988","volume":"8","author":"E O\u2019Hearn","year":"1988","unstructured":"O\u2019Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci. 1988;8:2788\u2013803.","journal-title":"J Neurosci"},{"key":"2248_CR44","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1111\/jnc.15348","volume":"157","author":"S Schenk","year":"2021","unstructured":"Schenk S, Highgate Q. Methylenedioxymethamphetamine (MDMA): serotonergic and dopaminergic mechanisms related to its use and misuse. J Neurochem. 2021;157:1714\u201324.","journal-title":"J Neurochem"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02248-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02248-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02248-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T23:02:22Z","timestamp":1765926142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02248-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2248"],"URL":"https:\/\/doi.org\/10.1038\/s41386-025-02248-3","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MEL is a consultant for Mind Medicine, Inc and Lykos Therapeutics. The other authors declare no conflicts of interest. Knowhow and data associated with this work are owned by the University Hospital Basel and were licensed by Mind Medicine, Inc. Mind Medicine, Inc., had no role in planning or conducting the present study or writing the publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}